Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736687 | 0.92 | HDAC3 (0.49) | HDAC3HDAC1HDAC2NCOR2CTSL | |
| SCHEMBL7983451 | 0.91 | HDAC3 (0.51) | HDAC3HDAC1HDAC2NCOR2CTSL | |
| SCHEMBL25047615 | 0.90 | HDAC3 (0.46) | HDAC3HDAC1HDAC2NCOR2MEN1 | |
| SCHEMBL30941082 | 0.89 | ALOX5 (0.50) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL25047455 | 0.88 | MEN1 (0.43) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL25047628 | 0.86 | SSTR4 (0.42) | HDAC3HDAC1HDAC2NCOR2ALDH1A1 | |
| SCHEMBL2722481 | 0.86 | HDAC3 (0.53) | HDAC3HDAC1HDAC2NCOR2CTSL | |
| SCHEMBL25047584 | 0.85 | HDAC1 (0.43) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL25047687 | 0.85 | MC4R (0.44) | HDAC3HDAC1HDAC2NCOR2CTSB | |
| SCHEMBL1797681 | 0.84 | HDAC1 (0.50) | HDAC3HDAC1HDAC2NCOR2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021053158-A1 | NOVEL HISTONE METHYLTRANSFERASE INHIBITORS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-03-25 | — | — | WO | disclosed |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-25 | — | — | US | disclosed |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170349578-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-20 | — | — | US | disclosed |
| EP-1341781-B1 | ANTIMICROBIAL QUINOLONES | PROCTER & GAMBLE (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040029882-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE CO. | 2004-02-12 | — | — | US | disclosed |
| US-6645981-B2 | For therapy of microbial infection | THE PROCTER & GAMBLE COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-1341781-A1 | ANTIMICROBIAL QUINOLONES | THE PROCTER & GAMBLE COMPANY (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2003-01-09 | — | — | US | disclosed |
| WO-2002048138-A1 | ANTIMICROBIAL QUINOLONES | THE PROCTER & GAMBLE COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-6214833-B1 | MADE BY ACYLATION | ZAMBON GROUP S.P.A. (IT) | 2001-04-10 | — | — | US | disclosed |
| EP-0970075-A1 | PYRIMIDINONE-1,3-OXATHIOLANE DERIVATIVES WITH ANTIVIRAL ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998043972-A1 | PYRIMIDINONE-1,3-OXATHIOLANE DERIVATIVES WITH ANTIVIRAL ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349578-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | HDAC3 451/4885HDAC1 295/4885HDAC2 743/4885 |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | HDAC3 2572/4885HDAC1 2681/4885HDAC2 3322/4885 |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | OPRM1, OPRD1, OGFR | HDAC3 207/4885HDAC1 217/4885HDAC2 269/4885 |
| US-20040029882-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | HDAC3 2572/4885HDAC1 2681/4885HDAC2 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.